2022
Chapter 2 Overview of liquid biopsy
Aghamir S, Khatami F, Yarandi V, Rezaeian A, Fiorentino M. Chapter 2 Overview of liquid biopsy. 2022, 5-30. DOI: 10.1016/b978-0-323-99884-0.00004-5.Peer-Reviewed Original ResearchLiquid biopsy analysisTumor-derived cellsLiquid biopsyBiopsy analysisCell-free circulating tumor DNAApplication of liquid biopsyLiquid biopsy componentsCharacterization of CTCsPredictive of responseDetection of mutationsMinimally invasive biomarkersTumor characteristicsLiquid biopsy dataUrogenital cancersTumor DNADroplet digital PCRBiopsy dataTherapeutic decisionsBiopsyNext-generation sequencingTumorInvasive biomarkersMedical strategiesCancerPersonalized medicine
2021
The importance of personalized medicine in urological cancers
Khatami F, Hassanzad M, Nikfar S, Guitynavard F, Karimaee S, Tamehri Zadeh S, Gholami K, Rezaeian A, Feiz-Abadi S, Jahanshahi F, Aghamir S. The importance of personalized medicine in urological cancers. Journal Of Diabetes & Metabolic Disorders 2021, 21: 841-852. PMID: 35673449, PMCID: PMC9167380, DOI: 10.1007/s40200-021-00824-0.Peer-Reviewed Original ResearchAndrogen deprivation therapyExcision repair cross-complementing group 1Prostate cancerAndrogen receptorUrological cancersResistance to androgen deprivation therapyPersonalized medicineAssociated with metastatic potentialAdvanced prostate cancerMetastatic bladder cancerPersonalized therapeutic regimensDNA-damaging chemotherapyDeprivation therapyAndrogen independenceMuscle-invasiveTargeted therapyTherapeutic regimensBladder cancerPoor prognosisMetastatic potentialTumor developmentGroup 1PTEN geneMolecular profilingCancer